Update promotional labeling and advertising promptly after a labeling change

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

Once FDA-approved labeling has been changed under 601.12(f)(1) or (f)(2), the holder of the approved biologics license application must promptly revise all promotional labeling and advertising so it is consistent with the new labeling.

Check

Compare claims, warnings, dosing, and other statements in the piece against the current approved labeling; a violation looks like promotional content that still reflects a superseded version of the labeling (e.g., an old indication, dosage, or missing a newly added warning) after a labeling change has been implemented.

Escalate when

The date of the underlying labeling change or the timeliness of the revision is unclear, or it is ambiguous whether a discrepancy reflects a not-yet-incorporated labeling change versus an unrelated inaccuracy.

Where this comes from

21 CFR 601.12(a)(4). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…ss of the product. (3) Notwithstanding the requirements of paragraphs (b), (c), and (f) of this section, an applicant must make a change provided for in those paragraphs in accordance with a regulation or guidance that provides for a less burdensome notification of the change (for example, by submission of a supplement that does not require approval prior to distribution of the product or in an annual report). (4) The applicant must promptly revise all promotional labeling and advertising to make it consistent with any labeling change implemented in accordance with paragraphs (f)(1) and (f)(2) of this section. (5) A supplement or annual report must include a list of all changes contained in the supplement or annual report. For supplements, this list must be provided in the cover letter. (b) Changes requiring supplement submission and approval prior to distribution of the product made using the change (major changes). (1) A supplement shall be submitted for any change in the product, production process, quality control…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 601.12
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: bac9eabe8f8844b1b69e5fa2…

Applies when

Naturepromotional

Productbiologic

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The substance is supported: 21 CFR 601.12(a)(4) says in mandatory terms that 'The applicant must promptly revise all promotional labeling and advertising to make it consistent with any labeling change implemented in accordance with paragraphs (f)(1) and (f)(2) of this section.' The rule statement tracks this, including the limitation to labeling changes implemented under (f)(1) and (f)(2) rather than to labeling changes generally.
- Overstated on scope: § 601.12 is a Part 601 biologics-licensing provision addressed to the holder of an approved biologics license application ('each change ... established in the approved license application(s)'). The rule's applies_when contains only {promotional: [promotional]} and so is written as applying to every product type, which is broader than what this source establishes. The companion rule US-ADM-011, drawn from the same section, does carry product-type: biologic, so the narrowing field is available and its absence here is an omission, not a schema limitation.
- Atomic: one obligation (conform promotional labeling and advertising to the changed labeling). The check's list of what to compare (claims, warnings, dosing) is guidance for applying the single requirement, not additional requirements.
- 'Judgment' is correct: both 'promptly' and 'consistent with' turn on assessment rather than a literal match, and the escalate condition acknowledges the timing ambiguity.
- Authority 'binding' is correct (codified regulation). Severity 'blocker' is defensible — promotional material inconsistent with current approved labeling is a substantive, not cosmetic, defect.
- The locator 21 CFR 601.12(a)(4) matches the quoted sentence exactly.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is the complete, verbatim sentence of 21 CFR 601.12(a)(4) and is an operative requirement in the regulatory text, not an example, definition or preamble.
- The rule statement tracks the source exactly: the obligation to promptly revise all promotional labeling and advertising so it is consistent with a labeling change implemented under (f)(1) or (f)(2). It neither broadens the trigger (it correctly limits it to (f)(1)/(f)(2) changes) nor softens it.
- Atomic: a single obligation - conform promotional materials to the changed approved labeling. The check lists several places a discrepancy could show up (claims, warnings, dosing), but that is one requirement checked in several spots, not bundled requirements.
- determinism 'judgment' is right: deciding whether a piece is 'consistent with' revised labeling, and whether the revision was 'prompt', turns on comparison and timing judgment rather than a literal match.
- authority 'binding' is correct and not overclaimed - 21 CFR 601.12 is a regulation and the source sentence says 'must'.
- applies_when is justified: 601.12 governs approved biologics license applications, so 'product-type: biologic' reflects the source's scope, and 'promotional' matches the sentence's own object ('promotional labeling and advertising').
- Locator 21 CFR 601.12(a)(4) is exactly where the quoted sentence sits.
- Severity 'blocker' is defensible: promotional material still reflecting superseded labeling (e.g. an omitted new warning or withdrawn indication) is a misbranding-level defect, not a stylistic one.
- Violable: a piece that still carries the superseded indication, dose or missing warning breaks it.